

Drug Policy

Policy:	201416	Initial Effective Date: 07/30/2014
Code(s):	J0897	Annual Review Date: 03/19/2024
SUBJECT:	Xgeva® (denosumab injection)	Last Revised Date:03/19/2024

Subject to Site of Care

Prior authorization applies to Medicare benefit

Prior approval is required for some or all procedure codes listed in this Corporate Medical.

HCPCS Code J0897 requires prior approval except when utilized for treatment/prevention of osteoporosis.

POLICY STATEMENT

This policy involves the use of Xgeva. Prior authorization is recommended for medical benefit coverage of Xgeva. Coverage is recommended for those who meet the conditions of coverage in the **Criteria, Dosing, Initial/Extended Approval, Duration of Therapy, and Labs/Diagnostics** for the diagnosis provided. The requirement that the patient meet the Criteria for coverage of the requested medication applies to the initial authorization only. **Waste Management** applies for all covered conditions. **Conditions not recommended for approval** are listed following the recommended authorization criteria and Waste Management section.

Because of the specialized skills required for evaluation and diagnosis of patients treated with Xgeva as well as the monitoring required for adverse events and long-term efficacy, initial approval for some conditions requires Xgeva to be prescribed by or in consultation with a physician who specializes in the condition being treated. All approvals for initial therapy are provided for the initial approval duration noted below; if reauthorization is required, a response to therapy is required for continuation of therapy.

Recommended Authorization Criteria

Coverage of Xgeva is recommended in those who meet the following criteria:

FDA-Approved Indications

- 1. Prevention of Skeletal-Related Events in Patients with Bone Metastases from Solid Tumors (e.g., Breast Cancer, Prostate Cancer, Non-Small-Cell Lung Cancer).** Approve for 6 months if the patient meets the following criteria (A, B, C and D):
 - A) The patient is aged \geq 18 years; AND
 - B) The agent is prescribed by, or in consultation with, a hematologist or an oncologist; AND
 - C) The patient has bone metastases; AND

This document is subject to the disclaimer found at <https://www.medmutual.com/For-Providers/Policies-and-Standards/CorporateMedicalDisclaimer.aspx> and is subject to change. Always verify with the most current version at <https://www.medmutual.com/For-Providers/Policies-and-Standards/CorporateMedicalDisclaimer.aspx> or <https://www.medmutual.com/For-Providers/Policies-and-Standards/Prescription-Drug-Resources.aspx>.

Drug Policy

- D) Patients with prostate cancer have received at least one hormonal therapy (e.g., Lupron Depot® [leuprolide for depot suspension], Eligard® [leuprolide acetate for injectable suspension], Trelstar® [triptorelin pamoate for injectable suspension], or Zoladex® [goserelin implant]).

Dosing. Approve 120 mg administered as a subcutaneous (SC) injection once every 4 weeks.

-
2. **Prevention of Skeletal-Related Events in Patients with Multiple Myeloma.**¹ Approve Xgeva for 6 months if the patient meets the following criteria (A and B):

- A) The patient is aged ≥ 18 years; AND
B) The agent is prescribed by, or in consultation with, a hematologist or an oncologist.

Dosing. Approve 120 mg administered as a subcutaneous (SC) injection once every 4 weeks.

-
3. **Giant Cell Tumor of Bone.** Approve for 6 months.

Dosing. Approve 120 mg SC once every 4 weeks with loading doses on Day 8 and Day 15 of Month 1.^{1,7}

-
4. **Hypercalcemia of Malignancy.** Approve for 2 months if the patient meets the following criteria (A, B, and C):

- A) The patient has a current malignancy; AND
B) The patient's albumin-corrected calcium (cCa) is ≥ 11.5 mg/dL.

Dosing. Approve 120 mg SC once every 4 weeks with additional 120 mg doses on Days 8 and 15 of the first month of therapy.¹

CONDITIONS NOT RECOMMENDED FOR APPROVAL

Xgeva has not been shown to be effective or there are limited or preliminary data, or potential safety concerns, that are not supportive of general approval for the following conditions. Rationale for non-coverage for these specific conditions are provided below.

1. Coverage is not recommended for circumstances *not* listed in the *Recommended Authorization Criteria*. Criteria will be updated as new published data are available.

Documentation Requirements:

The Company reserves the right to request additional documentation as part of its coverage determination process. The Company may deny reimbursement when it has determined that the drug provided or services performed were not

This document is subject to the disclaimer found at <https://www.medmutual.com/For-Providers/Policies-and-Standards/CorporateMedicalDisclaimer.aspx> and is subject to change. Always verify with the most current version at <https://www.medmutual.com/For-Providers/Policies-and-Standards/CorporateMedicalDisclaimer.aspx> or <https://www.medmutual.com/For-Providers/Policies-and-Standards/Prescription-Drug-Resources.aspx>.

Drug Policy

medically necessary, investigational or experimental, not within the scope of benefits afforded to the member and/or a pattern of billing or other practice has been found to be either inappropriate or excessive. Additional documentation supporting medical necessity for the services provided must be made available upon request to the Company. Documentation requested may include patient records, test results and/or credentials of the provider ordering or performing a service. The Company also reserves the right to modify, revise, change, apply and interpret this policy at its sole discretion, and the exercise of this discretion shall be final and binding.

REFERENCES

1. Xgeva® injection for subcutaneous use [prescribing information]. Thousand Oaks, CA: Amgen; June 2020.
2. Prolia® injection for subcutaneous use [prescribing information]. Thousand Oaks, CA: Amgen; May 2017.
3. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. *J Clin Oncol*. 2010;28(35):5132-5139.
4. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomized, double-blind study. *Lancet*. 2011;377:813-822.
5. Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. *J Clin Oncol*. 2011;29(9):1125-1132.
6. Van Poznak C, Somerfield MR, Barlow WE, et al. Role of bone-modifying agents in metastatic breast cancer: an American Society of Clinical Oncology-Cancer Care Ontario focused guideline update. *J Clin Oncol*. 2017;35(35):3978-3986.
7. Thomas D, Henshaw R, Skubitz K, et al. Denosumab in patients with giant-cell tumor of bone: an open-label, phase 2 study. *Lancet Oncol*. 2010;11:275-280.
8. Branstetter DG, Nelson SC, Carlos Manivel J, et al. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor bone. *Clin Cancer Res*. 2012;18:4415-4424.
9. The NCCN Bone Cancer Clinical Practice Guidelines in Oncology (Version 1.2018 – August 29, 2017). © 2017 National Comprehensive Cancer Network, Inc. Available at: <http://www.nccn.org>. Accessed on February 6, 2018.
10. Raskin KA, Schwab JH, Mankin HJ, et al. Giant cell tumor of bone. *J Am Acad Orthop Surg*. 2013;21(2):118-126.
11. Chakarun CJ, Forrester DM, Gottsegen CJ, et al. Giant cell tumor of bone: review, mimics, and new developments in treatment. *Radiographics*. 2013;33(1):197-211.
12. Chawla S, Henshaw R, Seeger L, et al. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. *Lancet Oncol*. 2013;14(9):901-908.
13. Hu MI, Glezerman IG, Leboulleux S, et al. Denosumab for treatment of hypercalcemia of malignancy. *J Clin Endocrinol Metab*. 2014;99:3144-3152.
14. Hu MI, Glezerman I, Leboulleux S, et al. Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment. *J Natl Cancer Inst*. 2013;105(18):1417-1420.
15. Zometa® injection for intravenous infusion [prescribing information]. East Hanover, NJ: Novartis; December 2016.

This document is subject to the disclaimer found at <https://www.medmutual.com/For-Providers/Policies-and-Standards/CorporateMedicalDisclaimer.aspx> and is subject to change. Always verify with the most current version at <https://www.medmutual.com/For-Providers/Policies-and-Standards/CorporateMedicalDisclaimer.aspx> or <https://www.medmutual.com/For-Providers/Policies-and-Standards/Prescription-Drug-Resources.aspx>.

Drug Policy

16. Aredia® injection [prescribing information]. East Hanover, NJ: Novartis; May 2012.
17. Anderson K, Ismaila N, Flynn PJ, et al. Role of bone-modifying agents in multiple myeloma: American Society of Clinical Oncology clinical practice guideline update. *J Clin Oncol*. 2018 Jan 17. [Epub ahead of print].
18. Palmerini E, Shawla NS, Ferrari S, et al. Denosumab in advanced/unresectable giant-cell tumour of bone (GCTB): for how long? *Eur J Cancer*. 2017;76:118-124.
19. The NCCN Multiple Myeloma Clinical Practice Guidelines in Oncology (Version 4.2018 – February 12, 2018). © 2017 National Comprehensive Cancer Network, Inc. Available at: <http://www.nccn.org>. Accessed on January 19, 2018.

FOR MEDICAL BENEFIT COVERAGE REQUESTS:

Prior approval is required for HCPCS Codes J0897

Edits and Denials:

Prior Approval: Prior approval is required for Xgeva (**HCPCS Code J0897**) except when utilized for treatment/prevention of osteoporosis. Requests for prior approval will be authorized by a nurse reviewer if submitted documentation meets criteria outlined within the Corporate Medical Policy.

Requests for prior approval will be forwarded to a qualified physician reviewer if submitted documentation does not meet criteria outlined within the Corporate Medical Policy.

TOPPS: Claims received with **HCPCS Code J0897** will edit with **Remark Code M3M** and will be adjudicated in accordance with the Corporate Medical Policy.

Liability: A participating provider will be required to write off charges denied as not medically necessary. A provider may bill a member for charges denied as investigational.

HCPCS Code(s):	
J0897	Injection, denosumab, 1 mg

This document is subject to the disclaimer found at <https://www.medmutual.com/For-Providers/Policies-and-Standards/CorporateMedicalDisclaimer.aspx> and is subject to change. Always verify with the most current version at <https://www.medmutual.com/For-Providers/Policies-and-Standards/CorporateMedicalDisclaimer.aspx> or <https://www.medmutual.com/For-Providers/Policies-and-Standards/Prescription-Drug-Resources.aspx>.